secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2025-04-02T23:59:59+00:00
Accession:  0001104659-25-030870
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Therapeutics prices $200M common stock offering at $20.13 per share
----------------------------------------------------------------------------

- 9,935,419 shares priced at $20.13; gross proceeds ~$200M before discounts and expenses.
- Closing expected April 3, 2025; anticipated cash runway through 2028 (including existing cash).
- Proceeds to fund sevasemten for Becker/Duchenne MD, EDG-7500 HCM trials, and R&D.
- Participants include Braidwell, Cormorant, Driehaus, Invus, Janus, MPM, OrbiMed, Paradigm, Perceptive, RA Capital, Sofinnova.
- Underwritten by Leerink, Piper Sandler, Guggenheim, and Truist Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925030870/0001104659-25-030870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465925030870/tm2510984d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-030870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer